NCT06832228
- Conditions
- Diffuse Large B-Cell Lymphoma (DLBCL), Hemic and Lymphatic Diseases, Immune System Diseases, +9 more
- Locations
-
- Zhejiang Cancer Hospital Hangzhou, Zhejiang, China
Clinical trial condition
Diffuse Large B-Cell Lymphoma (DLBCL)
Explore clinical trials studying Diffuse Large B-Cell Lymphoma (DLBCL). Study availability and eligibility vary by location and protocol.
47 public trials
21 recruiting studies
Diffuse Large B-Cell Lymphoma (DLBCL) trial results
Not yet recruiting
Epcoritamab in Combination With R-CHOP for Patients With Aggressive Non-Hodgkin Lymphoma
NCT07588698
- Conditions
- Diffuse Large B-Cell Lymphoma (DLBCL), Hemic and Lymphatic Diseases, Immune System Diseases, +11 more
- Locations
-
- Zuckerberg San Francisco General San Francisco, California, United States
- University of California, San Francisco San Francisco, California, United States
Not yet recruiting
Pomalidomide Plus Rituximab Maintenance in Young High-Risk Newly Diagnosed DLBCL After First-Line Response
NCT07760610
- Conditions
- Diffuse Large B-Cell Lymphoma (DLBCL), Hemic and Lymphatic Diseases, Immune System Diseases, +9 more
- Locations
-
Not specified
Not yet recruiting
Birelentinib Plus R-CHOP in Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma (TAI-SHAN19)
NCT07712588
- Conditions
- Diffuse Large B-Cell Lymphoma (DLBCL), Hemic and Lymphatic Diseases, Immune System Diseases, +9 more
- Locations
-
- Chongqing University Cancer Hospital Chongqing, Chongqing Municipality, China
- Harbin Medical University Cancer Hospital Harbin, Heilongjiang, China
- Hunan Cancer Hospital Changsha, Hunan, China
- Cancer Hospital of Shandong Frist Medical University Jinan, Shangdong, China
Not yet recruiting
Autologous IC-Nine, CD30 CAR, and Constitutive IL7R Expressing EBVST for CD30 Lymphoma (ANCILE-30)
NCT07729397
- Conditions
- Anaplastic Large Cell Lymphoma, ALK-Positive, Anaplastic Large Cell Lymphoma, ALK-negative, Diffuse Large B-Cell Lymphoma (DLBCL), +17 more
- Locations
-
- Houston Methodist Hospital Houston, Texas, United States
Not yet recruiting
Glofitamab Combined With Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
NCT07669194
- Conditions
- Diffuse Large B-Cell Lymphoma (DLBCL), Disease Attributes, Hemic and Lymphatic Diseases, +13 more
- Locations
-
- Second Affiliated Hospital, School of Medicine, Zhejiang University Hangzhou, Zhejiang, China
Not yet recruiting
A Phase Ⅰ Study of CS08399 in Participants With MTAP-deleted Solid Tumors and Lymphoma
NCT07583771
- Conditions
- Advanced Solid Tumors, Bronchial Neoplasms, Carcinoma, Bronchogenic, +21 more
- Locations
-
- Fudan University Shanghai Cancer Center Shanghai, China
- Conditions
- Adult B-cell Acute Lymphoblastic Leukemia, Burkitt Lymphoma, Chronic Disease, +31 more
- Locations
-
Not specified
Not yet recruiting
A Phase I/II Study of TRS005 in Combination With Cyclophosphamide, Doxorubicin, and Prednisone（T-CHP） in Previously Untreated Patients With CD20-positive DLBCL
NCT07035379
- Conditions
- Diffuse Large B-Cell Lymphoma (DLBCL), Hemic and Lymphatic Diseases, Immune System Diseases, +9 more
- Locations
-
- Chinese Academy of Medical Sciences, Cancer Hospital Beijing, Beijing Municipality, China
Not yet recruiting
Zanubrutinib in Maintenance Therapy of DLBCL Patients With Initial Remission
NCT05596097
- Conditions
- Diffuse Large B-Cell Lymphoma (DLBCL), Hemic and Lymphatic Diseases, Immune System Diseases, +9 more
- Locations
-
- The First Hospital of Lanzhou University Lanzhou, Gansu, China